An observational study in Schizophrenia, Bipolar Disorder and Psychiatric Issue, sponsored by Abant Izzet Baysal University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-27.
Sponsored by Abant Izzet Baysal University · Observational
In predominantly medication-naïve schizophrenic patients, those exhibiting partial metabolic disorders have significantly worse sleep quality and sleep onset time; poor sleep predicted metabolic dysregulation even after controlling for confounding factors. Mental health, sleep, and eating behavior interact in ways that strongly influence the risk of obesity and MetS. Emotional eating (eating in response to emotions rather than hunger) is central to this network and appears to be closely associated with psychiatric illnesses, particularly depression, anxiety, and sleep disorders. There is a continuing need to elucidate the frequency, level, and relationship of emotional eating with other factors in individuals with SMI. Therefore, this study aims to elucidate this complex relationship, thereby shedding light on new ways to reduce metabolic risks in psychiatric patients.
Research Questions
Hypotheses
H1 The group of psychotropic medications routinely used significantly affects MetS levels.
H2 Individuals with SMI have high levels of emotional eating.
H3 As mental status deteriorates, the level of emotional eating increases.
H4 Emotional eating mediates the relationship between mental status and MetS.
H5 Sleep quality mediates the relationship between mental status and MetS.
H6 Emotional eating and sleep quality mediate the relationship between mental status and MetS (multiple mediation model).
H7 As sleep quality decreases, emotional eating increases.
H8 As the level of emotional eating increases, sleep quality deteriorates, which increases the risk of metabolic syndrome.
3,563 studies on the registry are indexed under Schizophrenia; 491 are open to participants now.
This study's planned enrollment of 78 is below the median of 178 across 506 observational studies indexed under Schizophrenia.
Browse Schizophrenia studies →Abant Izzet Baysal University is the lead sponsor of 250 studies on the registry; 59 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Individuals being followed at the Community Mental Health Center, diagnosed with schizophrenia or bipolar disorder, who volunteered to participate in the study and were able to provide written consent.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metabolic Syndrome Risk
Participants' current metabolic syndrome risk scores will be measured using the Metabolic Syndrome Risk Index. The total score ranges from 0 to 100. A higher score indicates a higher risk of metabolic syndrome risk.
Time frame: Baseline
Emotional eating level
Participants' current emotional eating level scores will be measured using the Salzburg Emotional Eating Scale.
Time frame: Baseline
Sleep quality
Participants' current sleep quality scores will be measured using the Cumhuriyet Subjective Sleep Quality Scale.
Time frame: Baseline
Positive and negative symptom
Participants' current positive and negative symptom severity. This will be measured using Positive and Negative Syndrome Scale (PANSS). It measures the prevalence of positive and negative syndromes in schizophrenia. Scores range from 7-49 for the Positive and Negative Scales, and from 16-112 for the General Psychopathology Scale. The PANSS total score is a minimum of 30 and a maximum of 210. A higher score indicates higher symptom severity.
Time frame: Baseline
Manic symptom
Participants' current manic symptom severity. This will be measured using Young Mania Rating Scale. It measures the prevalence of manic symptom in bipolar disorders. The total score can range from 0 to 60; higher scores indicate more severe manic symptoms.
Time frame: Baseline
Depressive symptoms
Participants' current depressive symptoms severity. This will be measured using Hamilton Depression Rating Scale. It measures the prevalence of depressive symptom. In general, the higher the total score, the more severe the depression. HAM-D depression score levels: 10-13 mild; 14-17 mild to moderate; \>17 moderate to severe; \>23 very severe. Total score ranges from 0 to 68.
Time frame: Baseline
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Abant Izzet Baysal University →